Details of the Drug Combinations
General Information of This Drug (ID: DM79VXT)
Drug Name | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
Ertugliflozin; 1210344-57-2; PF04971729; UNII-6C282481IP; PF 04971729; CHEMBL1770248; 6C282481IP; AK174928; 1,6-Anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-5-C-(hydroxymethyl)-beta-L-idopyranose; Steglatro; (1S,2S,3S,4R,5S)-5-(4-chloro-3-(4-ethoxybenzyl)phenyl)-1-(hydroxymethyl)-6,8-dioxabicyclo[321]octane-2,3,4-triol; (1S,2S,3S,4R,5S)-5-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-1-(hydroxymethyl)-6,8-dioxabicyclo[321]octane-2,3,4-triol; Ertugliflozin [USAN:INN]; C22H25ClO7; PF-4971729; SGLT2 inhibitor (oral, type 2 diabetes), Pfizer; Sodium glucose cotransporter-2 inhibitor (oral, type 2 diabetes), Pfizer; Ertugliflozin/PF-04971729
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
List of Combinatorial Drugs (CBD) Containing This Drug
2 Clinical Trial Drug Combination(s) Consisting of This drug
|
||||||||||||||||||||||||||||||
References